NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab

NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab

Abstract Background Early identification of cardiac dysfunction by non-invasive imaging in HER2-positive breast cancer patients treated with trastuzumab is challenging. In particular multigated acquisition (MUGA) scan, which is most widely used, is unable to detect subclinical cardiac changes. The u...

Full description

Bibliographic Details
Main Authors: Nathalie I. Bouwer, Crista Liesting, Marcel J. M. Kofflard, Sylvia M. Sprangers-van Campen, Jasper J. Brugts, Jos J. E. M. Kitzen, Michael A. Fouraux, Mark-David Levin, Eric Boersma
Format: Article
Language:English
Published: BMC 2019-05-01
Series:Cardio-Oncology
Subjects:
Cardiotoxicity
HER2-positive breast cancer
NT-proBNP
Trastuzumab
LVEF decline
Online Access:http://link.springer.com/article/10.1186/s40959-019-0039-4

Internet

http://link.springer.com/article/10.1186/s40959-019-0039-4

Similar Items